Lu L, Lu X, Luo W. Personalized cancer vaccines: current advances and emerging horizons. Vaccines (Basel). 2025;13(12):1231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montin D, Santilli V, Beni A, Costagliola G, Martire B, Mastrototaro MF, et al. Towards personalized vaccines. Front Immunol. 2024;15:1436108. https://doi.org/10.3389/fimmu.2024.1436108

Alaqeel NK. Advances in personalized cancer vaccine to nanotechnology innovations. Cancer Treat Res Commun. 2026;46:101060.

PubMed  Google Scholar 

Iamukova L, Alferova E. Personalized cancer vaccines in the clinical trial pipeline. Asia-Pac J Clin Oncol. 2025. https://doi.org/10.1111/ajco.70006.

Article  PubMed  PubMed Central  Google Scholar 

Fritah H, Rovelli R, Chiang CL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022;106:102383. https://doi.org/10.1016/j.ctrv.2022.102383.

Article  PubMed  Google Scholar 

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–9.

Article  CAS  PubMed  Google Scholar 

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82.

Article  CAS  PubMed  Google Scholar 

Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (Sudbury Mass). 2011;17(5):343–50.

Article  CAS  Google Scholar 

Zahedipour F, Jamialahmadi K, Zamani P, Reza Jaafari M. Improving the efficacy of peptide vaccines in cancer immunotherapy. Int Immunopharmacol. 2023;123:110721.

Article  CAS  PubMed  Google Scholar 

Laila UE, An W, Xu ZX. Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy. Front Immunol. 2024;15:1448489. https://doi.org/10.3389/fimmu.2024.1448489

Quan Y, Yang H, Li W, Li L. mRNA vaccines: immunogenicity and quality characteristics. J Nanobiotechnol. 2025;24(1):6.

Article  Google Scholar 

Li J-y, Jiang R-y, Wang J, Wang X-j. Advances in mRNA vaccine therapy for breast cancer research. Discov Oncol. 2025;16(1):673.

Article  PubMed  PubMed Central  Google Scholar 

Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6.

Article  CAS  PubMed  Google Scholar 

Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403(10432):1192–204.

Article  CAS  PubMed  Google Scholar 

Sanchari B, Nilufa E, Atanu P, Aditi N, Debjeet S. mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects. Protein Pept Lett. 2026;33:1–15.

Google Scholar 

Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024;24(3):213–27.

Article  CAS  PubMed  Google Scholar 

Sadat Larijani M, Sadat SM, Bolhassani A, Ramezani A. A Shot at Dendritic Cell-Based Vaccine Strategy against HIV-1. JoMMID. 2019;7(4):89.

Article  Google Scholar 

Lee KW, Yam JWP, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023;12(17):2147. https://doi.org/10.3390/cells12172147.

Article  PubMed  PubMed Central  Google Scholar 

Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11(5):653–68.

Article  PubMed  Google Scholar 

Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–60.

Article  CAS  PubMed  Google Scholar 

Yu Z, Wang D, Qi Y, Liu J, Zhou T, Rao W, et al. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Mater Horiz. 2023;10(5):1661–77.

Article  CAS  PubMed  Google Scholar 

Wang D, Yu Z, Qi Y, Hu K, Zhou T, Liu J, et al. Liquid metal nanoplatform based autologous cancer vaccines. ACS Nano. 2023;17(14):13278–95.

Article  CAS  PubMed  Google Scholar 

Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5):404–14.

Article  CAS  PubMed  Google Scholar 

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):1638212.

Article  Google Scholar 

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci (New York NY). 2018;359(6382):1361–5.

Article  CAS  Google Scholar 

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.

Article  PubMed  PubMed Central  Google Scholar 

Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin cancer research: official J Am Association Cancer Res. 2016;22(8):1897–906.

Article  CAS  Google Scholar 

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Volume 348. New York, NY: Science; 2015. pp. 803–8. 6236.

Google Scholar 

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.

Article  CAS